CMC, Bioprocessing & Scale-Up Blog - Smart Biotech Scientist

Innovation

Neither Small Molecule nor Biologic: The Cyclodextrin Dimer CMC Challenge – Part 1

What if the boldest therapeutic breakthroughs begin with questioning the very boxes we use to define drugs?

Innovation

Neither Small Molecule nor Biologic: The Cyclodextrin Dimer CMC Challenge – Part 1

What if the boldest therapeutic breakthroughs begin with questioning the very boxes we use to define drugs?

Innovation

Neither Small Molecule nor Biologic: The Cyclodextrin Dimer CMC Challenge – Part 1

What if the boldest therapeutic breakthroughs begin with questioning the very boxes we use to define drugs?

CMC and Bioprocess Blog

Execution-focused articles on CMC strategy, bioprocess scale-up, tech transfer, CDMO selection, and GMP readiness for process development scientists and manufacturing leaders scaling biologics into regulatory-ready therapies.

Data & Analytics

Your Bioprocess Data Already Holds 35% More Yield: From End-to-End Models to Digital Twins – Part 1

Is your bioprocess development stacked with siloed data, endless spreadsheets, and a constant battle to identify where to start your digital transformation?

Innovation

From Lab-Scale Molding to GMP: Manufacturing a Collagen Implant for the Clinic – Part 2

Translating science into real-world impact isn’t just about groundbreaking ideas—it’s a marathon of mindset, collaboration, and clarity.

Innovation

From Lab-Scale Molding to GMP: Manufacturing a Collagen Implant for the Clinic – Part 1

What if healing large tissue gaps was less about replacing what’s lost, and more about empowering the body to mend itself?

Innovation

Engineering iPSC Neurons for Parkinson’s: From 3% Survival to Durable Graft – Part 2

What does it actually take to turn a cell therapy idea into a viable therapeutic—especially when the hurdles are higher than ever and every experiment carries real consequences for your runway?

Innovation

Engineering iPSC Neurons for Parkinson’s: From 3% Survival to Durable Graft – Part 1

When it comes to neurodegenerative disease, few diagnoses evoke as much dread as Parkinson’s.

Innovation

From Static Scaffolds to Dynamic Matrices: Hydrogels for Animal-Free 3D Cell Culture – Part 2

How much of your research lives and dies on the bench—not because the idea isn’t sound, but because building reproducible, scalable biomaterials remains an unsolved puzzle?

Bioprocessing

Nitrosamine Risk Assessment and CRO Selection: The $6 Million Mistake CMC Teams Must Avoid – Part 2

Getting an NDA signed shouldn’t feel like waiting for FDA approval. If your CRO needs weeks just to kickstart paperwork…

Bioprocessing

Nitrosamine Risk Assessment and CRO Selection: The $6 Million Mistake CMC Teams Must Avoid – Part 1

When drug safety fails, patients—and entire markets—pay the price. Understanding your CMC isn’t just compliance; it’s the line between therapeutic promise and product recall.

Bioprocessing

Why Your Shake Flask Culture Doesn’t Scale: OTR, Shaking Diameter, and How to Fix It – Part 2

What’s the real difference between a shake flask, a microtiter plate, and a full-scale bioreactor—and why do so many experiments go sideways, even when the SOP looks perfect?

Bioprocessing

Why Your Shake Flask Culture Doesn’t Scale: OTR, Shaking Diameter, and How to Fix It – Part 1

In bioprocess development, orbital-shaken bioreactors—shake flasks, spin tubes, and microtiter plates—are the unsung backbone powering industry decisions about production strains and media.

Bioprocessing

Prevent the Delays That Derail Biologics Tech Transfer: 12-Week Protocol for CMC

What if the difference between a seamless tech transfer and a costly setback isn’t your process, but how you orchestrate the people and details behind the scenes?

Bioprocessing

Turn Tech Transfer from a Gamble into a Managed Process: The 6-Pillar Biologics Scale-Up Framework

Tech transfer in biotech can feel like a high-stakes gamble, balancing regulatory shifts, incomplete data, and mounting stakeholder pressure—all with timelines breathing down your neck.

Data & Analytics

Why Your Dormant Omics Data Is Worth More Than the Data You’ll Generate Next – Part 2

What does it take to crack the code of protein production—and why do some proteins stubbornly refuse to cooperate, despite the best efforts of scientists and engineers?

Data & Analytics

Why Your Dormant Omics Data Is Worth More Than the Data You’ll Generate Next – Part 1

Somewhere in your lab, a hard drive is quietly storing omics data that hasn’t seen the light of day in years—genome sequences, metabolomics runs, scribbled notes in aging ELNs.

Data & Analytics

Your Bioprocess Data Already Holds 35% More Yield: From End-to-End Models to Digital Twins – Part 2

Leveraging digital models and AI-powered tools can make all the difference for both R&D and manufacturing, but finding the right starting point—and justifying the investment—can feel overwhelming.

Data & Analytics

Your Bioprocess Data Already Holds 35% More Yield: From End-to-End Models to Digital Twins – Part 1

Is your bioprocess development stacked with siloed data, endless spreadsheets, and a constant battle to identify where to start your digital transformation?

Data & Analytics

Why AI and Automation Tools Won’t Deliver Until Your Lab’s Data Is Connected – Part 2

What separates labs with truly connected, AI-ready data from those drowning in digital chaos?

Data & Analytics

Why AI and Automation Tools Won’t Deliver Until Your Lab’s Data Is Connected – Part 1

What if the real bottleneck in biotech labs isn’t equipment, talent, or even funding—but a silent issue lurking in plain sight: fragmented data?

Biotech Success

Why Most Bioprocess Automation Projects Fail Before the Robot Is Even Ordered – Part 2

Complex automation often arrives wrapped in hype, but the reality is more nuanced.

Biotech Success

Why Most Bioprocess Automation Projects Fail Before the Robot Is Even Ordered – Part 1

Are you struggling with automation projects that spiral into unnecessary complexity or fail to solve the real problem in bioprocessing?

Biotech Success

From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success – Part 2

Biologics manufacturing success is built—not salvaged—from day one. Overlook CMC fundamentals, and you’re architecting your own failure.

Biotech Success

From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success – Part 1

How solid is your CMC foundation—and what happens if it cracks under pressure?

Biotech Success

Media-Based Glycan Engineering for Biosimilars: Your Rapid Implementation Guide

When raffinose works, when it doesn’t, and a 3-experiment protocol to validate it for your process in 8 weeks.

Biotech Success

Media-Based Glycan Engineering for Biosimilars: Achieving Reference Product Match

Why pistachios sabotaged cyclists’ performance — and the raffinose mechanism behind it.

Innovation

Neither Small Molecule nor Biologic: The Cyclodextrin Dimer CMC Challenge – Part 1

What if the boldest therapeutic breakthroughs begin with questioning the very boxes we use to define drugs?

Innovation

Batch-to-Batch Variability Is a Design Failure, Not the Norm – Part 2

Biotech startups face a labyrinth of decisions when it comes to manufacturing strategy.

Innovation

Batch-to-Batch Variability Is a Design Failure, Not the Norm – Part 1

What if batch-to-batch variability was no longer just “part of the job” in tissue engineering and in vitro biology?

Innovation

Detecting 1 in 100,000 Cells: DNA Barcoding for Smarter Clone Selection – Part 2

Cell line development in biotech is a race against time and complexity, with innovators constantly seeking solutions that provide robust and scalable data for manufacturability and regulatory demands.

Innovation

Detecting 1 in 100,000 Cells: DNA Barcoding for Smarter Clone Selection – Part 1

Cloning workflows have long relied on brute force: screen more cells, automate harder, and hope that small-scale performance predicts manufacturability.

Innovation

When Your Delivery Vehicle Contains a Membrane Protein: CMC Decisions With No Regulatory Precedent – Part 2

Biopharma faces mounting pressure to develop safer, more efficient platforms for delivering nucleic acid therapies, especially as regulatory agencies scrutinize novel formulations and excipients.

Enjoying what you're reading? Get the next deep-dive and digest in your inbox.

The Bioprocess Brief — biweekly digests, deep-dives, and field notes on biologics, cell and gene therapies, and AI-driven bioprocessing, written by a CMC practitioner.

No spam. Unsubscribe anytime.

Enjoying what you're reading? Get the next deep-dive and digest in your inbox.

The Bioprocess Brief — biweekly digests, deep-dives, and field notes on biologics, cell and gene therapies, and AI-driven bioprocessing, written by a CMC practitioner.

No spam. Unsubscribe anytime.

Innovation

Dr. David Brühlmann

Innovation

Dr. David Brühlmann

Innovation

Dr. David Brühlmann

CMC and Bioprocess Blog

Data & Analytics

Innovation

Innovation

Innovation

Innovation

Innovation

Bioprocessing

Bioprocessing

Bioprocessing

Bioprocessing

Bioprocessing

Bioprocessing

Data & Analytics

Data & Analytics

Data & Analytics

Data & Analytics

Data & Analytics

Data & Analytics

Biotech Success

Biotech Success

Biotech Success

Biotech Success

Biotech Success

Biotech Success

Innovation

Innovation

Innovation

Innovation

Innovation

Innovation

Enjoying what you're reading? Get the next deep-dive and digest in your inbox.

Enjoying what you're reading? Get the next deep-dive and digest in your inbox.